Effect of Older vs Younger Age on Anthropometric and Metabolic Variables During Treatment of Psychotic Depression With Sertraline Plus Olanzapine: The STOP-PD II Study.

TitleEffect of Older vs Younger Age on Anthropometric and Metabolic Variables During Treatment of Psychotic Depression With Sertraline Plus Olanzapine: The STOP-PD II Study.
Publication TypeJournal Article
Year of Publication2021
AuthorsFlint AJ, Rothschild AJ, Whyte EM, Alexopoulos GS, Mulsant BH, Marino P, Banerjee S, Pollari CD, Wu Y, Voineskos AN, Meyers BS
Corporate AuthorsSTOP-PD II Study Group
JournalAm J Geriatr Psychiatry
Volume29
Issue7
Pagination645-654
Date Published2021 Jul
ISSN1545-7214
KeywordsAdolescent, Adult, Aged, Aged, 80 and over, Antipsychotic Agents, Benzodiazepines, Depression, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Olanzapine, Sertraline, Treatment Outcome, Young Adult
Abstract

OBJECTIVE: To examine the effect of older versus younger age on change in anthropometric and metabolic measures during extended treatment of psychotic depression with sertraline plus olanzapine.

METHODS: Two hundred and sixty-nine men and women aged 18-85 years with an episode of psychotic depression were treated with open-label sertraline plus olanzapine for up to 12 weeks. Participants who remained in remission following an 8-week stabilization phase were eligible to participate in a 36-week randomized controlled trial (RCT) that compared the efficacy and tolerability of sertraline plus olanzapine with sertraline plus placebo. Weight, waist circumference and plasma lipids, glucose, HbA1c, and insulin were measured at regular intervals during the acute, stabilization and randomized phases of the study. Linear mixed models were used to analyze the trajectories of anthropometric and metabolic measures.

RESULTS: Participants aged 60 years or older experienced less weight gain and less increase in cholesterol during the combined acute and stabilization phases of the study compared with those aged 18-59 years. At the acute-stabilization termination visit, mean weight in older participants was 6.5 lb. less than premorbid weight, whereas it was 17.9 lb. more than premorbid weight in younger participants. In the RCT, there was a significant interaction of treatment and age group for the trajectory of weight, but the post hoc tests that compared age groups within each treatment arm were not statistically significant. There were no clinically significant differences between younger and older participants in glycemic measures.

CONCLUSION: Older patients with psychotic depression experienced less increase in weight and total cholesterol than their younger counterparts during acute and stabilization treatment with sertraline plus olanzapine. In the older group, weight gained during the acute and stabilization phases appeared to be partial restoration of weight lost during the index episode of depression, whereas weight gain in younger participants was not.

DOI10.1016/j.jagp.2020.11.003
Alternate JournalAm J Geriatr Psychiatry
PubMed ID33268022
PubMed Central IDPMC8121896
Grant ListU01 MH062518 / MH / NIMH NIH HHS / United States
U01 MH062446 / MH / NIMH NIH HHS / United States
UL1 TR002384 / TR / NCATS NIH HHS / United States
U01 MH062624 / MH / NIMH NIH HHS / United States
U01 MH062565 / MH / NIMH NIH HHS / United States